REGENERON PHARMACEUTICALS, INC. - 8-K Filing
Regeneron reports Q3 2026 revenue of $5.1 billion, a 36% increase year-over-year, driven by strong Dupixent and EYLEA HD sales. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $REGN